|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM219B |
Gene summary for FAM219B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM219B | Gene ID | 57184 |
| Gene name | family with sequence similarity 219 member B | |
| Gene Alias | C15orf17 | |
| Cytomap | 15q24.1-q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | Q5XKK7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57184 | FAM219B | LZE7T | Human | Esophagus | ESCC | 2.14e-04 | 1.72e-01 | 0.0667 |
| 57184 | FAM219B | LZE24T | Human | Esophagus | ESCC | 1.02e-06 | 1.42e-01 | 0.0596 |
| 57184 | FAM219B | P1T-E | Human | Esophagus | ESCC | 1.90e-08 | 3.38e-01 | 0.0875 |
| 57184 | FAM219B | P2T-E | Human | Esophagus | ESCC | 1.17e-16 | 1.66e-01 | 0.1177 |
| 57184 | FAM219B | P4T-E | Human | Esophagus | ESCC | 3.41e-12 | 2.45e-01 | 0.1323 |
| 57184 | FAM219B | P5T-E | Human | Esophagus | ESCC | 8.98e-10 | 3.03e-02 | 0.1327 |
| 57184 | FAM219B | P8T-E | Human | Esophagus | ESCC | 5.16e-10 | 1.76e-01 | 0.0889 |
| 57184 | FAM219B | P9T-E | Human | Esophagus | ESCC | 3.45e-05 | 1.64e-01 | 0.1131 |
| 57184 | FAM219B | P10T-E | Human | Esophagus | ESCC | 1.74e-32 | 4.21e-01 | 0.116 |
| 57184 | FAM219B | P12T-E | Human | Esophagus | ESCC | 1.21e-19 | 2.81e-01 | 0.1122 |
| 57184 | FAM219B | P15T-E | Human | Esophagus | ESCC | 1.02e-21 | 2.84e-01 | 0.1149 |
| 57184 | FAM219B | P16T-E | Human | Esophagus | ESCC | 4.16e-25 | 3.65e-01 | 0.1153 |
| 57184 | FAM219B | P19T-E | Human | Esophagus | ESCC | 3.49e-11 | 4.42e-01 | 0.1662 |
| 57184 | FAM219B | P20T-E | Human | Esophagus | ESCC | 1.02e-08 | 1.50e-01 | 0.1124 |
| 57184 | FAM219B | P21T-E | Human | Esophagus | ESCC | 3.64e-14 | 1.98e-01 | 0.1617 |
| 57184 | FAM219B | P22T-E | Human | Esophagus | ESCC | 7.87e-13 | 2.26e-01 | 0.1236 |
| 57184 | FAM219B | P23T-E | Human | Esophagus | ESCC | 5.79e-10 | 2.14e-01 | 0.108 |
| 57184 | FAM219B | P24T-E | Human | Esophagus | ESCC | 4.08e-13 | 6.95e-02 | 0.1287 |
| 57184 | FAM219B | P26T-E | Human | Esophagus | ESCC | 3.59e-15 | 2.52e-01 | 0.1276 |
| 57184 | FAM219B | P27T-E | Human | Esophagus | ESCC | 8.50e-22 | 2.44e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM219B | SNV | Missense_Mutation | c.346C>T | p.Pro116Ser | p.P116S | Q5XKK7 | protein_coding | deleterious(0.03) | benign(0.187) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FAM219B | SNV | Missense_Mutation | c.272N>T | p.Ser91Leu | p.S91L | Q5XKK7 | protein_coding | tolerated(0.24) | benign(0) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| FAM219B | SNV | Missense_Mutation | c.301N>G | p.Arg101Gly | p.R101G | Q5XKK7 | protein_coding | deleterious(0) | benign(0.026) | TCGA-G4-6302-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM219B | SNV | Missense_Mutation | rs765652617 | c.370N>A | p.Asp124Asn | p.D124N | Q5XKK7 | protein_coding | deleterious(0.04) | benign(0.095) | TCGA-AJ-A3NE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM219B | SNV | Missense_Mutation | novel | c.424N>A | p.Ala142Thr | p.A142T | Q5XKK7 | protein_coding | deleterious(0) | possibly_damaging(0.859) | TCGA-C9-A480-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |